A detailed history of Charles Schwab Investment Management Inc transactions in Vera Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 361,805 shares of VERA stock, worth $15.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
361,805
Previous 351,088 3.05%
Holding current value
$15.4 Million
Previous $12.7 Million 25.87%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$34.09 - $46.71 $365,342 - $500,591
10,717 Added 3.05%
361,805 $16 Million
Q2 2024

Aug 12, 2024

BUY
$33.72 - $48.82 $426,996 - $618,207
12,663 Added 3.74%
351,088 $12.7 Million
Q1 2024

May 08, 2024

BUY
$14.91 - $49.14 $901,592 - $2.97 Million
60,469 Added 21.75%
338,425 $14.6 Million
Q4 2023

Feb 06, 2024

BUY
$9.29 - $16.0 $101,744 - $175,232
10,952 Added 4.1%
277,956 $4.27 Million
Q3 2023

Nov 08, 2023

BUY
$13.71 - $19.64 $2.42 Million - $3.47 Million
176,473 Added 194.93%
267,004 $3.66 Million
Q2 2023

Aug 09, 2023

BUY
$6.11 - $17.83 $177,874 - $519,066
29,112 Added 47.4%
90,531 $1.45 Million
Q1 2023

May 11, 2023

BUY
$5.41 - $18.3 $122,049 - $412,848
22,560 Added 58.06%
61,419 $476,000
Q4 2022

Feb 13, 2023

BUY
$15.74 - $22.19 $15,252 - $21,502
969 Added 2.56%
38,859 $751,000
Q3 2022

Nov 14, 2022

BUY
$13.27 - $22.31 $42,450 - $71,369
3,199 Added 9.22%
37,890 $808,000
Q2 2022

Aug 15, 2022

SELL
$12.82 - $23.4 $666 - $1,216
-52 Reduced 0.15%
34,691 $473,000
Q1 2022

May 13, 2022

BUY
$17.8 - $28.06 $200,267 - $315,703
11,251 Added 47.89%
34,743 $817,000
Q4 2021

Feb 11, 2022

BUY
$15.01 - $35.8 $98,225 - $234,275
6,544 Added 38.61%
23,492 $628,000
Q3 2021

Nov 16, 2021

BUY
$13.71 - $30.6 $232,357 - $518,608
16,948 New
16,948 $295,000

Others Institutions Holding VERA

About Vera Therapeutics, Inc.


  • Ticker VERA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,042,300
  • Market Cap $1.15B
  • Description
  • Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...
More about VERA
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.